Biofilms: A developmental niche for vancomycin-intermediate Staphylococcus aureus

被引:0
|
作者
Chapman, Jenelle E. [1 ]
George, Shilpa E. [2 ]
Wolz, Christiane [2 ]
Olson, Michael E. [1 ,3 ]
机构
[1] Southern Illinois Univ, Dept Med Microbiol Immunol & Cell Biol, Sch Med, Springfield, IL USA
[2] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Tubingen, Germany
[3] 800 N Rutledge St, Springfield, IL 62702 USA
关键词
Staphylococcus aureus; Biofilm; Insurance hypothesis; DNA repair; Vancomycin; COMPLETE GENOME SEQUENCE; SOS RESPONSE; ANTIBIOTIC-RESISTANCE; 2-COMPONENT SYSTEM; GENE; MECHANISMS; PROTEIN; STRAIN; EPIDEMIOLOGY; INFECTIONS;
D O I
10.1016/j.meegid.2023.105545
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Staphylococcus aureus are gram-positive bacteria responsible for a wide array of diseases, ranging from skin and soft tissue infections to more chronic illnesses such as toxic shock syndrome, osteomyelitis, and endocarditis. Vancomycin is currently one of the most effective antibiotics available in treating patients infected with methicillin-resistant S. aureus (MRSA), however the emergence of vancomycin-resistant S. aureus (VRSA), and more commonly vancomycin-intermediate S. aureus (VISA), threaten the future efficacy of vancomycin. Intermediate resistance to vancomycin occurs due to mutations within the loci of Staphylococcal genes involved in cell wall formation such as rpoB, graS, and yycG. We hypothesized the VISA phenotype may also arise as a result of the natural stress occurring within S. aureus biofilms, and that this phenomenon is mediated by the RecA/SOS response. Wildtype and recA null mutant/lexAG94E strains of S. aureus biofilms were established in biofilm microtiter assays or planktonic cultures with or without the addition of sub-inhibitory concentrations of vancomycin (0.063 mg/l - 0.25 mg/L ciprofloxacin, 0.5 mg/l vancomycin). Efficiency of plating techniques were used to quantify the subpopulation of biofilm-derived S. aureus cells that developed vancomycin-intermediate resistance. The results indicated that a greater subpopulation of cells from wildtype biofilms (4.16 x 102 CFUs) emerged from intermediate-resistant concentrations of vancomycin (4 mu g/ml) compared with the planktonic counterpart (1.53 x 101 CFUs). Wildtype biofilms (4.16 x 102 CFUs) also exhibited greater resistance to intermediate-resistant concentrations of vancomycin compared with strains deficient in the recA null mutant (8.15 x 101 CFUs) and lexA genes (8.00 x 101 CFUs). While the VISA phenotype would be an unintended consequence of genetic diversity and potentially gene transfer in the biofilm setting, it demonstrates that mutations occurring within biofilms allow for S. aureus to adapt to new environments, including the presence of widely used antibiotics.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
    Cui, LZ
    Tominaga, E
    Neoh, HM
    Hiramatsu, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 1079 - 1082
  • [42] Novel Mutation Sites in the Development of Vancomycin-Intermediate Resistance in Staphylococcus aureus
    Wang, Yubing
    Li, Xiaoli
    Jiang, Libo
    Han, Wentao
    Xie, Xiangming
    Jin, Yi
    He, Xiaoqing
    Wu, Rongling
    FRONTIERS IN MICROBIOLOGY, 2017, 7
  • [43] The msaABCR Operon Regulates Resistance in Vancomycin-Intermediate Staphylococcus aureus Strains
    Samanta, Dhritiman
    Elasri, Mohamed O.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6685 - 6695
  • [44] Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
    Howden, Benjamin P.
    Davies, John K.
    Johnson, Paul D. R.
    Stinear, Timothy P.
    Grayson, M. Lindsay
    CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) : 99 - +
  • [45] Exposure of Staphylococcus aureus to Subinhibitory Concentrations of β-Lactam Antibiotics Induces Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Roch, Melanie
    Clair, Perrine
    Renzoni, Adriana
    Reverdy, Marie-Elisabeth
    Dauwalder, Olivier
    Bes, Michele
    Martra, Annie
    Freydiere, Anne-Marie
    Laurent, Frederic
    Reix, Philippe
    Dumitrescu, Oana
    Vandenesch, Francois
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (09) : 5306 - 5314
  • [46] Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains
    Mehes, Leonora
    Tasko, Szilvia
    Szekely, Annamaria
    Toth, Akos
    Ungvari, Erika
    Erdei, Iren
    Dombradi, Zsuzsanna
    Szabo, Judit
    Marodi, Laszlo
    JOURNAL OF MEDICAL MICROBIOLOGY, 2012, 61 (02) : 198 - 203
  • [47] Accurate assessment of heterogeneous vancomycin-intermediate Staphylococcus aureus nasal carriage
    Charles, PGP
    Howden, BP
    Ward, PB
    Bishop, EJ
    Johnson, PDR
    Grayson, ML
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (07) : 1071 - 1072
  • [48] Moenomycin-resistance is associated with vancomycin-intermediate susceptibility in Staphylococcus aureus
    Nishi, H
    Komatsuzawa, H
    Yamada, S
    Fujiwara, T
    Ohara, M
    Ohta, K
    Sugiyama, M
    Ishikawa, T
    Sugai, M
    MICROBIOLOGY AND IMMUNOLOGY, 2003, 47 (12) : 927 - 935
  • [49] Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
    Liang, Jin
    Hu, Yuanfang
    Fu, Mingxia
    Li, Na
    Wang, Fengxia
    Yu, Xiaojun
    Ji, Bing
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 379 - 388
  • [50] Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance
    Neoh, Hui-Min
    Cui, Longzhu
    Yuzawa, Harumi
    Takeuchi, Fumihiko
    Matsuo, Miki
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (01) : 45 - 53